La cadena de opciones muestra datos clave de las opciones de acciones de Mural Oncology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Mural Oncology..

Mural Oncology (NASDAQ:MURA) Bolsa, Cadena de Opciones

Mural Oncology

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Mural Oncology PLC

Murakami Corp

Murano Global Investments PLC - Ordinary Shares

Murano Global Investments PLC

MURATA MFG INC ORD by Murata Manufacturing Inc.

Murata Manufacturing Co Ltd

MURATA MFG INC UNSP/ADR by Murata Manufacturing Inc.

Needham analyst David Saxon reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) from Hold to Hold.

News

Reiteration

Analyst Ratings

GMED

Needham Reiterates Hold on Globus Medicalto Hold

Guidance

USEA

United Maritime Says Long-term Fundamentals Of Dry Bulk Market Remain Strong

Biotech

Earnings

Health Care

General

PYXS

As Of December 31, 2024, Pyxis Oncology Had Cash And Cash Equivalents Of $128.4M That Is Expected To Provide Cash Runway Into The Second Half Of 2026

Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.09) by 21.1 percent. This is a 28.65 percent increase over losses of $(1.85) per share from the same period last year. The company reported quarterly sales of $16.15 million which beat the analyst consensus estimate of $13.81 million by 16.89 percent.

Pyxis Oncology FY 2024 GAAP EPS $(1.32) Misses $(1.09) Estimate, Sales $16.15M Beat $13.81M Estimate

UBS analyst Steven Fisher downgrades PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Buy to Neutral and announces $108 price target.

Downgrades

Price Target

PCAR

UBS Downgrades PACCAR to Neutral, Announces $108 Price Target

NCNO

Sandbox Banking's Glyue Introduced In The Zoom App Marketplace

United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.41) by 80.49 percent. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $10.80 million which beat the analyst consensus estimate of $9.50 million by 13.68 percent. This is a 6.90 percent decrease over sales of $11.60 million the same period last year.

Earnings Beats

United Maritime Q4 2024 Adj EPS $(0.08) Beats $(0.41) Estimate, Sales $10.80M Beat $9.50M Estimate

VRAX

Virax Biolabs Enrolls First Patients In Its UK Based Clinical Study Assessing T Cell Dysfunction In Post-acute Infection Syndromes

Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.53) by 66.04 percent. This is a 70 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $22.60 million which beat the analyst consensus estimate of $4.28 million by 428.04 percent. This is a 706.85 percent increase over sales of $2.80 million the same period last year.

STOK

Stoke Therapeutics Q4 2024 GAAP EPS $(0.18) Beats $(0.53) Estimate, Sales $22.60M Beat $4.28M Estimate

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $64 to $66.

RYTM

Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $66

Chinese EV maker&nbsp;XPeng&nbsp;Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares are trading lower premarket on Tuesday. The company reported&nbsp;fiscal&nbsp;fourth-quarter sales growth of&nbsp;23.4%&nbsp;year-on-year to 16.11 billion Chinese Yuan&nbsp;($2.21&nbsp;billion), topping the&nbsp;consensus estimate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44372075/xpeng-reports-fourth-quarter-and-fiscal-year-2024-unaudited-financial-results" rel="noreferrer noopener">of&nbsp;16.02 billion Chinese Yuan</a>.&nbsp;
Total revenues increased 59.4% sequentially in the quarter. The Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival's quarterly vehicle deliveries increased 52.1% Y/Y to 91,507. XPeng's physical sales network had 690 stores, covering 226 cities as of December 31, 2024.
XPeng's self-operated charging station network reached 1,920 stations as of December 31, 2024. Revenues from vehicle sales increased 20.0% Y/Y to 14.67 billion Chinese Yuan ($2.01 billion) on higher deliveries.
Gross margin was 14.4% versus 6.2% a year ago. Vehicle margin was 10.0% versus 4.1% a year ago, primarily attributable to the cost reduction. Operating loss for the quarter was 1.56 billion Chinese Yuan ($0.21 billion). 
Adjusted net loss per ADS of 1.47 Chinese Yuan missed the analyst consensus estimate for a loss of 1.35 Chinese Yuan. In USD terms, the adjusted earnings <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">per ADS was a loss of 20 cents</a> in-line with the consensus of 20 cents loss.
The&nbsp;company held&nbsp;$5.75 billion&nbsp;in cash and equivalents&nbsp;as of December 31, 2024.
Read: <a target="_blank" href="https://www.benzinga.com/25/03/44240449/tesla-rival-xpeng-eyes-138-billion-investment-in-humanoid-robots-says-chinese-state-media" rel="noreferrer noopener">Tesla Rival XPeng Eyes $13.8 Billion Investment In Humanoid Robots, Says Chinese State Media</a>
Chairman and CEO of XPENG, Xiaopeng He, highlighted the company&#8217;s strategic positioning to expand its market share in the Smart EV sector both in China and internationally.
He emphasized that AI will play a crucial role in advancing L3 and L4 autonomous driving within the automotive industry. The company&#8217;s goal is to establish XPENG as a globally recognized AI-driven automotive company and a smart technology brand that resonates with users worldwide.
Outlook: XPENG projects first-quarter vehicle deliveries between 91,000 and 93,000, reflecting <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">a surge of 317% to 326.8% Y/Y</a>.
The company anticipates revenue of 15 billion Chinese Yuan to 15.7 billion Chinese Yuan, vs. the consensus of 14.684 billion Chinese Yuan.
Investors can gain exposure to the stock via&nbsp;VanEck Low Carbon Energy ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMOG#NYSE">SMOG</a>) and Invesco WilderHill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>).
Price Action: XPEV shares are down 0.49% at $24.44 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44267567/xpeng-hesai-group-kohls-groupon-and-tesla-why-these-5-stocks-are-on-investors-radars-today" target="_blank" rel="noreferrer noopener">Xpeng, Hesai Group, Kohl&#8217;s, Groupon, And Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Movers

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

SMOG

TSLA

XPEV

Tesla's China Rival XPeng Delivers Over 91,500 EVs In Q4, Eyes Massive Growth In Q1

UBS analyst Brian Meredith upgrades Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) from Neutral to Buy and raises the price target from $344 to $395.

Upgrades

UBS Upgrades Willis Towers Watson to Buy, Raises Price Target to $395

HC Wainwright &amp; Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) with a Buy and raises the price target from $11 to $12.

BDTX

HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $12

ADTX

Appili Therapeutics Submits Applications For Four New Federal Funding Opportunities

Barclays analyst Lauren Lieberman downgrades PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and lowers the price target from $168 to $156.

Barclays Downgrades PepsiCo to Equal-Weight, Lowers Price Target to $156

LASE

Laser Photonics Enhances Gantry Laser Technology In Partnership With Subsidiary Control Micro Systems

Mizuho analyst Maheep Mandloi initiates coverage on Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Neutral rating and announces Price Target of $28.

Initiation

Mizuho Initiates Coverage On Bloom Energy with Neutral Rating, Announces Price Target of $28

OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) reported quarterly losses of $(2.18) per share. This is a 600.96 percent decrease over losses of $(0.31) per share from the same period last year. The company reported $57.78 million in sales this quarter. This is a 54.97 percent decrease over sales of $128.31 million the same period last year.

OCFT

OneConnect Financial Tech Q4 EPS $(2.18) Down From $(0.31) YoY, Sales $57.78M Down From $128.31M YoY

Jefferies analyst Edison Lee upgrades GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) from Hold to Buy and announces $45 price target.

Jefferies Upgrades GDS Holdings to Buy, Announces $45 Price Target

Jefferies analyst Julien Dumoulin-Smith downgrades TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) from Hold to Underperform and lowers the price target from $2.3 to $0.5.

TPIC

Jefferies Downgrades TPI Composites to Underperform, Lowers Price Target to $0.5

Press Releases

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Mural Oncology to Participate in Two Upcoming Investor Conferences

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

Comments

Mural Oncology

Mural Oncology (MURA) Opciones

Mural Oncology (NASDAQ:MURA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL